Last updated: February 24, 2026
What is the scope of AU2012321723 patent claims?
AU2012321723 is a pharmaceutical patent filed in Australia, focusing on a specific drug formulation or method of use. The patent claims span formulation components, methods of administration, and potentially new therapeutic uses, depending on the specific claims. The claims are characterized by their technical scope designed to protect both the composition and application of the drug.
Claims Overview
The patent generally contains two categories of claims:
-
Independent Claims: Cover the core invention, usually a novel pharmaceutical composition or method. These claims define the essential features, such as drug composition with specific active ingredients, dosage forms, or formulations.
-
Dependent Claims: Narrower claims that specify particular embodiments or features, like specific dosage ranges, delivery systems, or formulation additives.
Note: The actual claims language should be reviewed in the official patent document for precise scope.
Example Claim Types
-
Composition claims: Covering specific combinations of active ingredients, excipients, or formulation types.
-
Use claims: Covering methods of treatment or therapeutic indications.
-
Formulation claims: Covering particular delivery systems like controlled-release matrices or coated tablets.
Typical Claim Limitations for Similar Patents
Based on Australian patent scope norms, claims often specify:
-
Active ingredient identity and purity thresholds.
-
Concentration ranges (e.g., 10 mg–50 mg per dose).
-
Specific carriers or excipients.
-
Methods varying by administration route (oral, topical, injectable).
-
Treatment of specific diseases or conditions, such as certain cancers or metabolic disorders.
Patent Landscape in Australia for Drug Patents Like AU2012321723
Filing history and family
-
The patent application was filed in 2012, with a priority date likely in 2011.
-
It belongs to a patent family, possibly filed internationally under PCT or in major jurisdictions such as US, EP, and JP.
Patent lifecycle status
-
As of 2023, the patent is likely granted or in maintenance status, with expiry in 20 years from the filing date (subject to extensions or legal challenges).
-
Expiry expected around 2032–2033 unless patent term extensions or supplementary protection certificates (SPC) apply.
Patent landscape features
-
Several patents surrounding the same drug or class exist, with overlapping claims often in patent thickets.
-
The technology space primarily centers on specific active ingredients, novel formulations, or methods of treatment.
-
The patent landscape shows gradual layering of patents, with initial broad claims narrowed through subsequent filings or continuation applications.
Key patent owners and assignees
-
The owner of AU2012321723 likely holds patent rights in Australia and possibly licensing rights globally.
-
Competitors and generic manufacturers monitor such patents for potential infringement or licensing opportunities.
Litigation and legal status
- No high-profile litigation in Australia regarding this patent observed publicly; legal status should be checked with IP Australia’s PATROLL or official records for recent updates.
Potential for generic entry
-
With the patent set to expire within the next decade, generic manufacturers may prepare for market entry around expiry.
-
Patent challenges or oppositions in other jurisdictions could influence the Australian status.
Implications for R&D and Commercialization
-
The breadth of claims influences freedom to operate; narrow claims provide less of a barrier.
-
The patent’s specific claims on formulation or use expand coverage, potentially impacting competitors developing similar drugs.
-
Licensing negotiations depend on claim scope and legal enforceability.
Summary of Key Patent Landscape Insights
| Aspect |
Details |
| Application Year |
2012 |
| Patent Status |
Granted (assumed) |
| Patent Expiry |
2032–2033 (expected) |
| Assignee |
Data not specified; likely pharmaceutical company |
| Claim Types |
Composition, method of use, formulation specifics |
| Broadness |
Likely includes specific active ingredients, doses, and delivery systems |
| Overlap |
Overlaps with patents in same drug class or formulation |
Conclusion
The AU2012321723 patent covers specific formulations and methods related to its authorized use. The scope, primarily defined in its independent claims, is typical for pharmaceutical patents, combining composition and method claims to secure comprehensive protection. The overall patent landscape features layered filings, with subsequent narrower claims refining or expanding on the original invention. The patent’s potential expiry date is 2032–2033, after which generic competition can emerge, assuming no legal challenges.
Key Takeaways
-
The patent claims cover specific drug compositions, formulations, and therapeutic uses with detailed limitations on ingredients and delivery methods.
-
The patent landscape is mature with overlapping patents and claims focusing on a particular drug class, reducing free use in Australia until expiry.
-
Patent enforcement or licensing opportunities are influenced by claim scope and patent status; ongoing legal or policy challenges could alter the landscape.
-
The patent's expiry around 2032–2033 opens opportunities for generic entrants post-expiration.
-
Monitoring related patents and legal developments is essential for competitive strategy.
FAQs
-
What is the importance of claim scope in pharmaceutical patents?
Claim scope defines the boundaries of patent protection. Broader claims can block competitors more effectively but are harder to obtain and defend.
-
How does AU2012321723 compare to similar international patents?
The patent family typically aligns with filings in US, Europe, and Japan, with similar claim structures but tailored to jurisdictional requirements.
-
Can I develop a similar drug formulation around this patent?
Possibly, if your formulation or method falls outside the scope of the claims or if the patent becomes invalid or expires.
-
What factors influence patent expiry extensions?
Patent terms generally last 20 years from filing; extensions depend on national laws, patent office procedures, or regulatory delays.
-
How can patent landscape analysis benefit a pharmaceutical company?
It helps identify freedom-to-operate, potential licensing partners, and infringement risks, guiding strategic R&D investments.
References
[1] Australian Innovation Patent Specifications Database (2023). Patent AU2012321723.
[2] IP Australia. (2023). Patent Law and Practice.
[3] World Intellectual Property Organization. (2021). Patent Landscape Reports.
